Zai Lab Ltd - Asset Resilience Ratio
Zai Lab Ltd (ZLAB) has an Asset Resilience Ratio of 0.93% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zai Lab Ltd (ZLAB) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Zai Lab Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Zai Lab Ltd.
Liquid Assets Composition Over Time
This chart breaks down Zai Lab Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ZLAB long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.00 Million | 0.93% |
| Total Liquid Assets | $10.00 Million | 0.93% |
Asset Resilience Insights
- Limited Liquidity: Zai Lab Ltd maintains only 0.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zai Lab Ltd Industry Peers by Asset Resilience Ratio
Compare Zai Lab Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Zai Lab Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Zai Lab Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.85% | $10.00 Million | $1.17 Billion | -26.98pp |
| 2024-12-31 | 27.83% | $330.00 Million | $1.19 Billion | +26.26pp |
| 2023-12-31 | 1.57% | $16.30 Million | $1.04 Billion | -- |
| 2022-12-31 | 0.00% | $0.00 | $1.22 Billion | -- |
| 2021-12-31 | 27.64% | $445.00 Million | $1.61 Billion | -29.75pp |
| 2020-12-31 | 57.39% | $744.68 Million | $1.30 Billion | +1.07pp |
| 2019-12-31 | 56.31% | $200.00 Million | $355.15 Million | -10.03pp |
| 2018-12-31 | 66.34% | $200.35 Million | $301.99 Million | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more